A 62-year-old Japanese man presented with chest pain indicating that acute myocardial infarction had occurred. Eleven years earlier, he underwent a splenectomy due to idiopathic portal hypertension. Coronary angiography revealed diffuse stenosis, with calcification in the left anterior descending coronary artery (LAD). We performed a primary percutaneous coronary intervention (PCI). We deployed two drug-eluting stents with sufficient minimal cross-sectional stent area by intravascular ultrasound and thrombolysis in myocardial infarction (TIMI) 3 flow. The initial laboratory examination revealed chronic disseminated intravascular coagulation (DIC). On the 8th hospital day, he developed chest pain indicating early coronary stent thrombosis, although he had been prescribed dual antiplatelet therapy. We performed an emergent second PCI, and the TIMI flow grade improved from 0 to 3. Clopidogrel was replaced with prasugrel. On the 18th hospital day, we detected a repeated coronary stent thrombosis again. We performed a third PCI and the TIMI flow grade improved from 0 to 3. After anticoagulation therapy with warfarin, the DIC was improved and his condition ran a benign course without the recurrence of stent thrombosis for 1 month. Contrast-enhanced CT showed portal vein thrombosis. This patient's case reveals the possibility that the condition of chronic DIC can lead to recurrent stent thrombosis. Stent thrombosis is infrequent, but remains a serious complication in terms of morbidity and mortality. Although stent thrombosis is multifactorial, the present case suggests that DIC is a factor in stent thrombosis. To prevent stent thrombosis after PCI under DIC, anticoagulation might be a treatment option in addition to antiplatelet therapy. (Int Heart J 2017; 58: 988-992) 
P rimary percutaneous coronary intervention (PCI) is recommended for the treatment of an ST-elevation myocardial infarction (STEMI) by the 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines for STEMI. 1) Although primary PCI provides beneficial effects by improving the prognosis of a STEMI in not only the acute phase but also the chronic phase, stent thrombosis following the deployment of a bare metal stent or a drug-eluting stent (DES) remains a serious potential complication. And its occurrence is associated with significant (40-50%) mortality and a composite death/myocardial infarction (MI) rate of 50-70%. 2, 3) The three proposed main causes of stent thrombosis after PCI for a STEMI are as follows: 1) technical factors, 4) e.g., stent under-expansion and residual reference segment stenosis; 2) a culprit lesion, e.g., long lesion or calcification; 5) and 3) individual factors, e.g., heparin-induced thrombocytopenia (HIT), 6, 7) CYP2C9 genetic polymorphism, 8) and protein C deficiency and antithrombin-III deficiency. 9) Disseminated intravascular coagulation (DIC) is a clinicopathologic syndrome characterized by widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural anticoagulant mechanisms. Here we report a very rare case of recurrent early coronary stent thrombosis due to chronic DIC.
Case Report
A 62-year-old Japanese man was admitted to our hospital with chest pain. He had undergone a living donor kidney transplantation due to chronic glomerulonephritis 30 years earlier, but his renal function gradually worsened and he underwent a second living donor kidney transplantation. He had been prescribed tacrolimus 3 mg/day, mycophenolate mofetil 500 mg/day, and methylprednisolone 4 mg/day. He also underwent a splenectomy 11 years prior to his present admission because of idiopathic portal hypertension. He then developed portal vein thrombosis RECURRENT EARLY CORONARY STENT THROMBOSIS (PVT) and was prescribed warfarin for 6 months, a regimen that he adhered to until the PVT disappeared.
Three years prior to his present admission, echocardiography showed hypokinesis at the posterior wall of the left ventricle, but he declined to undergo coronary angiography (CAG) at that time because he had no symptoms and was concerned about contrast-induced nephropathy. He was prescribed clopidogrel 75 mg/day and bisoprolol 2.5 mg/day. On admission to our hospital, he had diabetes mellitus and hypertension as coronary risk factors and was prescribed linagliptin 5 mg/day, voglibose 0.6 mg/day, and telmisartan 20 mg/day. He had no remarkable family history and had never smoked tobacco products.
On admission, his physical examination was unremarkable for any significant abnormalities. His electrocardiogram (ECG) showed a normal sinus rhythm and ST elevation in leads V1-V4. He was started on aspirin at a loading dose of 200 mg. In addition, troponin T was positive; thus, we urgently diagnosed him as having an acute myocardial infarction (AMI). We performed emergency CAG. The CAG revealed diffuse stenosis with calcification in the left anterior descending coronary artery (LAD) ( Figure 1A ). We performed PCI.
Because the intravascular ultrasound (IVUS) catheter (OptiCross, Boston Scientific, Marlborough, MA, USA) could not cross the lesion, we performed a rotational coronary atherectomy using a 1.25-mm burr (Rotalink Plus System; Boston Scientific) and excimer laser coronary angioplasty (ELCA) using a 0.9-mm ELCA catheter (Vitesse RX; Spectranetics, Colorado Springs, CO). After the dilatation of a 2.0-mm balloon catheter (LAXA; Goodman, Nagoya, Japan) ( Figure Figure 1G ). The initial laboratory examination revealed a platelet count of 88,000 /μL and a D-dimer level of 44.7 μg/mL (Table) .
On the 8th hospital day, the patient developed chest pain and an ECG revealed an ST-segment elevation in leads V1-V4. Cardiac catheterization showed an early stent thrombosis of the initially placed stent, although the patient had been prescribed dual antiplatelet therapy (DAPT) and the PCI that had been performed was appropriate ( Figure 2 ). IVUS did not show stent underexpansion, stent deformation, or edge dissection, although it showed insignificant malapposition at the proximal edge. We performed ELCA using a 0.9-mm ELCA catheter and long inflation using a 3.0-mm perfusion balloon (Ryusei; Kaneka, Osaka, Japan). The TIMI flow grade improved from 0 to 3. Clopidogrel 75 mg/day was replaced with prasugrel 3.75 mg/day, taking into consideration that relatively many Japanese are poor metabolizers of CYP2C19. We performed a platelet coagulation test using a PA200C platelet aggregation analyzer (Kowa, Tokyo). The maximum light transmission was 12% and 31% (5 μM ADP and 20 μM ADP). Platelet aggregation was suppressed by aspirin and prasugrel. As shown in Figure 3 , on the 18th hospital day, he complained of chest pain and an ECG showed recurrent ST-segment elevations in V1-V4. Cardiac catheterization showed a stent thrombosis of the initially placed stent a second time. We performed thrombectomy using a thrombectomy catheter (Thrombuster; Kaneka) and long inflation using a 3.0-mm perfusion balloon (Ryusei). The TIMI flow grade improved from 0 to 3. In addition, he was started on heparin because a left ventricular thrombus was suspected by echocardiography. After the anticoagulation therapy, the patient's platelet count increased and his D-dimer level decreased. We continued anticoagulation therapy with warfarin because his DIC improved.
We performed a contrast-enhanced CT scan for the purpose of finding a common cause of DIC, such as a malignancy. The contrast-enhanced CT scan showed PVT, and no malignancy (Figure 4) , demonstrating that the condition of chronic DIC can lead to recurrent stent thrombosis. We excluded HIT, CYP2C9 genetic polymorphism, protein C deficiency, protein S deficiency, and antithrombin-III deficiency as causes of the recurrent stent thrombosis. On the 50th hospital day, the patient was discharged because his condition had run a benign course without a recurrence of stent thrombosis for 1 month. We learned later that he died shortly after discharge.
Discussion
Our patient had repeated early coronary stent thrombosis after PCI in the LAD even though he was prescribed DAPT. After anticoagulation therapy, no recurrence of coronary stent thrombosis occurred for a month. Unfortunately, he died suddenly after discharge. It is not clear whether his sudden death could have been caused by recurrent stent thrombosis. The sudden death might be explained by the occurrence of fatal arrhythmia, as his cardiac function was severely reduced (the ejection fraction was 30%) and 24-hour Holter electrocardiography showed non-sustained ventricular tachycardia (20 runs of premature ventricular contractions). An additional option, such as a wearable or implantable cardio-defibrillator, may therefore be needed in similar cases for the prevention of sudden death.
Although HIT, CYP2C19 genetic polymorphism, protein C deficiency, protein S deficiency, and antithrombin-III deficiency have been reported to occur in early stent thrombosis as individual factors, we were able to exclude those factors in this case. The possibility of stent thrombosis induced by a technical factor should be low because we accurately performed the PCI, although the culprit lesion in this case, which was long and calcified, might be an anatomical risk factor for stent thrombosis. PVT, which was eventually identified in this case, has been shown to cause chronic DIC. Our patient's case demonstrates the possibility that the condition of chronic DIC can lead to recurrent stent thrombosis.
DIC has been defined as a clinicopathologic syndrome characterized by widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural anticoagulant mechanisms. There have been some reports that DIC could possibly cause an AMI. [10] [11] [12] In addition, Ueda et al. reported that in 184 autopsied patients with DIC, coronary thrombosis and fresh MI were present in 31 and 16 autopsies, respectively. 13) Those previous studies could confirm the association between DIC and stent thrombosis.
When we performed a systematic survey of the U.S. National Library of Medicine's PubMed database using RECURRENT EARLY CORONARY STENT THROMBOSIS the key words "stent thrombosis" and "DIC", we found only one case report.
14) The authors of that case report concluded that DIC was a possible cause of stent thrombosis, but the diagnosis of DIC was based on abnormal laboratory results such as decreased fibrinogen, prolonged PT-international normalized ratio, and increased D-dimer after tissue plasminogen activator (t-PA) was administered. It is thus not clear whether the abnormal coagulation state was due to DIC or the use of t-PA.
In our patient, PVT had occurred after a splenectomy and he was prescribed warfarin for 6 months until the thrombus disappeared. PVT recurred 11 years later. Although the reported prevalence of PVT as an acute complication after splenectomy in patients who had splenomegaly is 12-29%, 15) its prevalence as a chronic complication after splenectomy is unknown. The present case indicates that PVT might develop in the chronic phase after a splenectomy. Regular monitoring to assess the presence of PVT would thus be appropriate after a splenectomy.
Stent under-expansion and residual reference segment stenosis have been associated with early stent thrombosis as technical factors. Long lesions and lesion calcification have also been associated with early stent thrombosis as anatomical factors. Our patient had these anatomical risk factors for stent thrombosis, and we performed the best strategy of PCI to minimize the risk of stent thrombosis.
He had been prescribed tacrolimus 3 mg/day, mycophenolate mofetil 500 mg/day, and methylprednisolone 4 mg/day. Although the relationship between immunosuppressive agents and AMI or early stent thrombosis is not yet clear, it was reported that a steroid-free immunosuppression regime reduced long-term cardiovascular morbidity in renal transplant recipients. 16) Therefore, steroids may be one of the risk factors for cardiovascular events in our patient.
Conclusion
Stent thrombosis is rare, but remains a serious complication because of a high chance of morbidity and mortality. Although stent thrombosis is multifactorial, the present case suggests that chronic DIC is one of the suspicious reasons for stent thrombosis. Anticoagulation might be an option in addition to antiplatelet therapy, to prevent stent thrombosis in patients with chronic DIC.
Disclosures

Conflicts of interest:
The authors declare that they have no conflicts of interest.
